Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Malignant Lymphoma

  Free Subscription


1 Am J Hematol
2 Am J Surg Pathol
3 Blood
2 Br J Haematol
1 Cancer Res
1 Haematologica
1 Int J Cancer
2 J Clin Oncol
1 J Virol
6 Leuk Lymphoma
1 Neurology
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. BAIR SM, Strelec L, Nagle SJ, Nasta SD, et al
    Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
    Am J Hematol. 2017 May 16. doi: 10.1002/ajh.24792.
    PubMed     Text format     Abstract available

    Am J Surg Pathol

  2. WALSH NM, Lano IM, Green P, Gallant C, et al
    AL Amyloidoma of the Skin/Subcutis: Cutaneous Amyloidosis, Plasma Cell Dyscrasia or a Manifestation of Primary Cutaneous Marginal Zone Lymphoma?
    Am J Surg Pathol. 2017 May 12. doi: 10.1097/PAS.0000000000000861.
    PubMed     Text format     Abstract available

  3. MITTELDORF C, Berisha A, Pfaltz MC, Broekaert SMC, et al
    Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Am J Surg Pathol. 2017 May 12. doi: 10.1097/PAS.0000000000000851.
    PubMed     Text format     Abstract available


  4. FANALE MA, Cheah CY, Rich A, Medeiros LJ, et al
    Encouraging activity for R-CHOP in Advanced Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma.
    Blood. 2017 May 18. pii: blood-2017-02-766121. doi: 10.1182/blood-2017-02-766121
    PubMed     Text format     Abstract available

  5. PEDERSEN MB, Hamilton-Dutoit SJ, Bendix K, Ketterling RP, et al
    DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study.
    Blood. 2017 May 18. pii: blood-2016-12-755496. doi: 10.1182/blood-2016-12-755496
    PubMed     Text format    

  6. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available

    Br J Haematol

  7. RUBIO-GONZALEZ B, Zain J, Rosen ST, Querfeld C, et al
    Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
    Br J Haematol. 2017;176:16-36.
    PubMed     Text format     Abstract available

  8. FONSECA E SILVA D, Lopes MS, Pedrosa C, Regadas L, et al
    Burkitt lymphoma.
    Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14758.
    PubMed     Text format    

    Cancer Res

  9. DAHAL LN, Dou L, Hussain K, Liu R, et al
    STING activation reverses lymphoma-mediated resistance to antibody immunotherapy.
    Cancer Res. 2017 May 16. pii: canres.2784.2016.
    PubMed     Text format     Abstract available


  10. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed     Text format    

    Int J Cancer

  11. ROTTENBERG Y, Levine H, Keinan-Boker L, Derazne E, et al
    Risk of nasopharyngeal carcinoma penetrates across immigrant generations: A migrant cohort study of 2.3 million Jewish Israeli adolescents.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30525.
    PubMed     Text format     Abstract available

    J Clin Oncol

    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed     Text format    

  13. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Text format     Abstract available

    J Virol

  14. MA SD, Tsai MH, Romero-Masters JC, Ranheim EA, et al
    Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  15. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available

  16. SUN HL, Atenafu EG, Tsang R, Kukreti V, et al
    Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 15:1-8. doi: 10.1080/10428194.2017.1307980.
    PubMed     Text format     Abstract available

  17. DYSHLOVOY SA, Rast S, Hauschild J, Otte K, et al
    Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.
    Leuk Lymphoma. 2017 May 16:1-11. doi: 10.1080/10428194.2017.1317091.
    PubMed     Text format     Abstract available

  18. WAGNER-JOHNSTON ND, Lensing S, Noy A, Ratner L, et al
    High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1317095.
    PubMed     Text format     Abstract available

  19. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    

  20. NAGAI H, Shimomura T, Takeuchi M, Hanada S, et al
    Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Leuk Lymphoma. 2017 May 16:1-7. doi: 10.1080/10428194.2017.1319054.
    PubMed     Text format     Abstract available


  21. HOSSACK M, McClean J
    Pure sensory ganglionopathy as the first sign of relapse in non-Hodgkin lymphoma.
    Neurology. 2017;88:1976-1977.
    PubMed     Text format    

    PLoS One

  22. BOYE P, Serres F, Marescaux L, Hordeaux J, et al
    Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma.
    PLoS One. 2017;12:e0177486.
    PubMed     Text format     Abstract available

  23. RENGSTL B, Kim S, Doring C, Weiser C, et al
    Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other.
    PLoS One. 2017;12:e0177378.
    PubMed     Text format     Abstract available

  24. MONDEJAR R, Perez C, Onaindia A, Martinez N, et al
    Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines.
    PLoS One. 2017;12:e0177524.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.